These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22353627)

  • 1. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
    Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
    Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
    Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].
    Kageyama S; Iwaki H; Masuda Y; Yoshida T; Narita M; Okada Y
    Hinyokika Kiyo; 2011 Apr; 57(4):203-7. PubMed ID: 21646852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
    Kuramoto T; Inagaki T; Fujii R; Sasaki Y; Nishizawa S; Nanpo Y; Matusmura N; Kohjimoto Y; Hara I
    Int J Clin Oncol; 2013 Oct; 18(5):890-7. PubMed ID: 22936562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
    Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients.
    Nakagami Y; Ohori M; Sakamoto N; Koga S; Hamada R; Hatano T; Tachibana M
    Int J Urol; 2010 Jul; 17(7):629-34. PubMed ID: 20438593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Shen Z; Yao Y
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
    Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
    Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.
    Minato A; Fujimoto N; Kubo T; Harada S; Akasaka S; Matsumoto T
    Med Oncol; 2012 Dec; 29(4):2895-900. PubMed ID: 22323054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
    Eymard JC; Priou F; Zannetti A; Ravaud A; Lepillé D; Kerbrat P; Gomez P; Paule B; Genet D; Hérait P; Ecstein-Fraïssé E; Joly F
    Ann Oncol; 2007 Jun; 18(6):1064-70. PubMed ID: 17434899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
    Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S
    Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.
    Li YF; Zhang SF; Zhang TT; Li L; Gan W; Jia HT; Xie S; Ji HH; He DL
    Asian J Androl; 2013 Nov; 15(6):773-9. PubMed ID: 23955552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.